Cardiovascular

Latest News

ckybe-stock.adobe.com
FDA Sets PDUFA Date for Acoramidis in Heart Failure Indication

February 5th 2024

The FDA has set an action date of Nov. 29, 2024, to review acoramidis to treat patients with transthyretin amyloid cardiomyopathy.

Express Scripts Lists Inpefa as Preferred on Medicare Formularies
Express Scripts Lists Inpefa as Preferred on Medicare Formularies

October 10th 2023

FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication

October 9th 2023

FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension
FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension

September 28th 2023

FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication

September 16th 2023

More News

© 2024 MJH Life Sciences

All rights reserved.